ADVERTISEMENT

ASCO 2023 – Combination Therapy Triples Survival Rate in Richter Syndrome

Masssimo Sandal   |   Conference Report   |   09 June 2023
ADVERTISEMENT

In a recent phase II clinical trial, MOLTO, completed in February 2023, a combination therapy of atezolizumab, obinutuzumab and venetoclax demonstrated a significant improvement in response and survival rates for patients with Richter syndrome, specifically those with diffuse large B-cell lymphoma ( RS -DLBCL).

A median survival of 31.6 months ...

          

September Challenge

Ends in 7d 17h
left
right

Topic Challenges

left
right